News

There are 3 FDA-approved medications available to treat opioid use disorder, and different treatment approaches that can aid patients on the road to recovery.

The chip was developed using cells from patients with and without ALS.

How the therapy is proving capable of giving patients the opportunity to slow down disease progression, while potentially increasing the health outcomes of patients and saving money.

Robert Chen, MD, and Hodgkin’s lymphoma patient, Jeremy Hernandez, speak on the challenges of receiving and treating a rare cancer diagnosis in young adults.

The FDA has approved Sandoz’s biosimilar, Hyrimoz (adalimumab-adaz), for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis in patients aged 4 years and older, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Who is the best candidate for invasive treatment in the GERD population?

Martha L. Twaddle, MD, reviews new updates in the 4th edition of National Clinical Guidelines for Palliative Care.

A total of 85% of study participants achieved virologic suppression (viral load

Added stigma further burdens the treatment of patients with opioid use disorder, but the medical community can do something about it.

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

Other risk factors included the age of conception, with women younger than 18 or older than 37 being at greatest risk.

The brain’s lymphatic vessels may offer a new way to treat multiple sclerosis.

The US Food and Drug Administration has approved TherapeuticsMD's TX-001HR (BIJUVA) for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Sodium oxybate (Xyrem) has been approved by the FDA for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years old with narcolepsy.

How increasing obesity rates have affected the prevalence of GERD and re-prioritized first-line care.

Lindsey Jennings, MD, MPH, and Carolyn Bogdon, MSN, FNP-BC, of Medical University of South Carolina discuss the challenges facing health care providers who are on the front line of battling the opioid epidemic.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

When successful, these relationships provide valuable insights to support strategies in many areas, including planning for clinical research, patient recruitment and education, reimbursement, access, compliance, and other areas.

Hispanic/Latina women in the US access HIV treatment at same rates as men despite facing greater challenges.

Too few physicians have the “soft” communications and interpersonal skills they need to succeed in clinical settings. That’s a big and potentially deadly problem.

With the FDA approval, Abbot now anticipates to offer new assays for use this fall.

Statistical analysis reveals cardiac effects of individual antiretrovirals in combination treatments for children infected with HIV perinatally.

Along with sports cardiology and pediatric cardiology, Robert Battle specializes in treating patients with hypertrophic cardiomyopathy, the most common genetic cardiovascular disorder.

The PicoAMH Elisa test, which measures the amount of Anti-Müllerian Hormone in the blood, was supported by data assessing 690 women.

Treating the blood clotting disorder thrombotic thrombocytopenic purpura might be possible through the use of a therapeutic enzyme.

The SynchroMed II myPTM Personal Therapy Manager allows patients with chronic pain to manage unpredictable pain by delivering on-demand doses within limits set by their provider.

The single-dose, oral therapy becomes the first new influenza antiviral with a novel mechanism of action approved by the FDA in nearly 20 years.

Switching antiepileptic drug manufacturer was found to increase the risk of seizure recurrence in a German population, contrary to findings in the US.

Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.

Men with Fabry disease develop white matter lesions much quicker than their female counterparts.